Literature DB >> 11643218

Ethics consultation: a dangerous, antidemocratic charlatanry?

Christian Lilje.   

Abstract

Giles Scofield's argument indicates ethics consultants may need to better clarify what in fact they are and what they are not doing, claiming, and striving for. But we must not step back too far. We must neither engage in putting in envious professional claims for exclusive rights in the area of difficult and momentous decisions in healthcare nor get stuck in discussing normative ethics at the level of metaphysics, ontology, and dogmatics (as has happened in Germany for decades). We must not do so especially in view of the achievements of ethics consultation and the growing demand for it by all parties involved, conceded even by sceptics. Ethics consultation, according to Scofield, appears to be dangerous....Let us look more closely at the logic of the argument by discussing the presumed "antidemocratic" nature. The "new tyranny" of thoughts, and the "proper" role of bioethics consultation. Some considerations about the possibility of ethics expertise shall be left for the end.

Keywords:  Bioethics and Professional Ethics

Mesh:

Year:  1993        PMID: 11643218

Source DB:  PubMed          Journal:  Camb Q Healthc Ethics        ISSN: 0963-1801            Impact factor:   1.284


  3 in total

1.  Should a medical/surgical specialist with formal training in bioethics provide health care ethics consultation in his/her own area of speciality?

Authors:  Mark Bernstein; Kerry Bowman
Journal:  HEC Forum       Date:  2003-09

2.  The professional status of bioethics consultation.

Authors:  Deborah Cummins
Journal:  Theor Med Bioeth       Date:  2002

3.  Quality attestation for clinical ethics consultants: a two-step model from the American Society for Bioethics and Humanities.

Authors:  Eric Kodish; Joseph J Fins; Clarence Braddock; Felicia Cohn; Nancy Neveloff Dubler; Marion Danis; Arthur R Derse; Robert A Pearlman; Martin Smith; Anita Tarzian; Stuart Youngner; Mark G Kuczewski
Journal:  Hastings Cent Rep       Date:  2013 Sep-Oct       Impact factor: 2.683

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.